$NURO
NeuroMetrix, Inc. Stock $nuro

$nuro Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000162828024008267 Filed on March 01, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$1.094M	$1.318M	$5.901M
YoY Change	-36.6%	-28.67%	-28.52%
Cost Of Revenue	$576.5K	$469.8K	$1.954M
YoY Change	9.53%	-23.9%	-22.02%
Gross Profit	$517.0K	$848.0K	$3.947M
YoY Change	-56.86%	-31.06%	-31.35%
Gross Profit Margin	47.28%	64.35%	66.89%
Selling, General & Admin	$2.827M	$1.973M	$8.321M
YoY Change	27.99%	27.42%	14.74%
% of Gross Profit	546.88%	232.64%	210.8%
Research & Development	$943.6K	$732.4K	$2.778M
YoY Change	34.9%	36.03%	-14.25%
% of Gross Profit	182.5%	86.37%	70.37%
Depreciation & Amortization	$24.91K	$25.71K	$55.71K
YoY Change	143.67%	151.57%	12.8%
% of Gross Profit	4.82%	3.03%	1.41%
Operating Expenses	$3.771M	$2.705M	$11.10M
YoY Change	29.66%	29.64%	5.78%
Operating Profit	-$3.254M	-$1.857M	-$7.152M
YoY Change	90.28%	116.83%	50.82%
Interest Expense	$19.16K	$9.410K	$257.1K
YoY Change			-20.93%
% of Operating Profit
Other Income/Expense, Net	$224.4K	$198.2K	$622.0K
YoY Change	65.13%	20.38%	91.3%
Pretax Income	-$3.030M	-$1.650M	-$6.529M
YoY Change	92.46%	138.42%	47.84%
Income Tax
% Of Pretax Income
Net Earnings	-$3.030M	-$1.650M	-$6.529M
YoY Change	92.45%	138.42%	47.84%
Net Earnings / Revenue	-277.04%	-125.18%	-110.64%
Basic Earnings Per Share	-$1.67		-$6.27
Diluted Earnings Per Share	-$1.67	-$1.43	-$6.27
COMMON SHARES
Basic Shares Outstanding	1.987M shares	8.591M shares	1.042M shares
Diluted Shares Outstanding	1.812M shares		1.042M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$17.60M	$18.00M	$18.00M
YoY Change	-13.11%	-15.11%	-15.11%
Cash & Equivalents	$1.260M	$1.732M	$1.732M
Short-Term Investments	$16.34M	$16.27M	$16.27M
Other Short-Term Assets	$611.7K	$779.0K	$779.0K
YoY Change	20.33%	-73.2%	-73.2%
Inventory	$1.471M	$1.559M	$1.559M
Prepaid Expenses
Receivables	$469.7K	$518.8K	$518.8K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$20.15M	$20.85M	$20.85M
YoY Change	-12.71%	-13.49%	-13.49%
LONG-TERM ASSETS
Property, Plant & Equipment	$268.5K	$293.4K	$543.6K
YoY Change	72.81%	77.18%	1.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$26.40K	$26.40K	$26.40K
YoY Change	0.0%	-95.31%	-95.31%
Total Long-Term Assets	$512.2K	$570.0K	$570.0K
YoY Change	-2.23%	1.31%	1.31%
TOTAL ASSETS
Total Short-Term Assets	$20.15M	$20.85M	$20.85M
Total Long-Term Assets	$512.2K	$570.0K	$570.0K
Total Assets	$20.66M	$21.42M	$21.42M
YoY Change	-12.48%	-13.15%	-13.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$144.6K	$215.5K	$215.5K
YoY Change	-63.89%	-41.45%	-41.45%
Accrued Expenses	$1.554M	$876.7K	$1.025M
YoY Change	79.0%	48.62%	38.84%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.847M	$1.241M	$1.241M
YoY Change	30.36%	12.13%	12.13%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$60.95K	$92.49K	$92.49K
YoY Change	-66.2%	-55.43%	-55.43%
Total Long-Term Liabilities	$60.95K	$92.49K	$92.49K
YoY Change	-66.2%	-55.43%	-55.43%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.847M	$1.241M	$1.241M
Total Long-Term Liabilities	$60.95K	$92.49K	$92.49K
Total Liabilities	$1.908M	$1.333M	$1.333M
YoY Change	19.46%	1.46%	1.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$213.1M	-$210.1M
YoY Change	3.89%	3.21%
Common Stock	$199.00	$152.00
YoY Change	-74.42%	-80.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$18.76M	$20.09M	$20.09M
YoY Change
Total Liabilities & Shareholders Equity	$20.66M	$21.42M	$21.42M
YoY Change	-12.48%	-13.15%	-13.15%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$3.030M	-$1.650M	-$6.529M
YoY Change	92.45%	138.42%	47.84%
Depreciation, Depletion And Amortization	$24.91K	$25.71K	$55.71K
YoY Change	143.67%	151.57%	12.8%
Cash From Operating Activities	-$2.081M	-$1.455M	-$6.085M
YoY Change	85.6%	-1.9%	15.04%
INVESTING ACTIVITIES
Capital Expenditures		$43.54K	$183.5K
YoY Change			691.74%
Acquisitions
YoY Change
Other Investing Activities	$138.3K	$139.9K	$1.340M
YoY Change	-116.52%	-93.18%	-107.94%
Cash From Investing Activities	$138.3K	$96.35K	$1.156M
YoY Change	-116.52%	-95.3%	-106.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.471M	1.625M	$2.325M
YoY Change		-15.04%	-39.82%
NET CHANGE
Cash From Operating Activities	-$2.081M	-1.455M	-$6.085M
Cash From Investing Activities	$138.3K	96.35K	$1.156M
Cash From Financing Activities	$1.471M	1.625M	$2.325M
Net Change In Cash	-$472.0K	266.9K	-$2.603M
YoY Change	-75.9%	-89.24%	-85.79%
FREE CASH FLOW
Cash From Operating Activities	-$2.081M	-$1.455M	-$6.085M
Capital Expenditures		$43.54K	$183.5K
Free Cash Flow		-$1.498M	-$6.268M
YoY Change		1.04%	17.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-33351
CY2023	dei	Entity Registrant Name EntityRegistrantName	NEUROMETRIX, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3308180
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	4B Gill Street
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Woburn
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01801
CY2023	dei	Local Phone Number LocalPhoneNumber	890-9989
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4955709	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4416609	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.97
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001289850
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	us-gaap	Substantial Doubt About Going Concern Within One Year SubstantialDoubtAboutGoingConcernWithinOneYear	false
CY2023	dei	City Area Code CityAreaCode	781
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	8183506	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1986540	shares
CY2023	dei	Auditor Firm AuditorFirmId	23
CY2023	dei	Auditor Name AuditorName	Baker Tilly US, LLP
CY2023	dei	Auditor Location AuditorLocation	Tewksbury, Massachusetts
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1731946	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4335020	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	16265205	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	usd
CY2023Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	0	usd
CY2022Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	16864707	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	25000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	25000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	518824	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	646771	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1559428	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1614987	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	779039	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	645502	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	20854442	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	24106987	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	293449	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	165619	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	250150	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	370609	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	26400	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	26400	usd
CY2023Q4	us-gaap	Assets Assets	21424441	usd
CY2022Q4	us-gaap	Assets Assets	24669615	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	215509	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	368082	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	876739	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	589939	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	148391	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	148391	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1240639	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1106412	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	92485	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	207516	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1333124	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1313928	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1524939	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1524939	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	971492	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	971492	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	152	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	96	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	229960346	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	226935456	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	240171	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-210109353	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-203579866	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	20091317	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	23355687	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21424441	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24669615	usd
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5901425	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8256073	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	1954012	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	2505833	usd
CY2023	us-gaap	Gross Profit GrossProfit	3947413	usd
CY2022	us-gaap	Gross Profit GrossProfit	5750240	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2777960	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3239725	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3365265	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2865615	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4386666	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	257105	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	325157	usd
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	364929	usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	622034	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	325157	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6529487	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.27
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.27
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.97
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	605100	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	0	usd
CY2023	nuro	Other Comprehensive Income Realized Gain Adjustment OtherComprehensiveIncomeRealizedGainAdjustment	364929	usd
CY2022	nuro	Other Comprehensive Income Realized Gain Adjustment OtherComprehensiveIncomeRealizedGainAdjustment	0	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6289316	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4416609	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	23215786	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	477062	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3833772	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	215417	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	30259	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4416609	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	23355687	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	699505	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2305753	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	19688	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	usd
CY2023	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	605100	usd
CY2023	nuro	Other Comprehensive Income Realized Gain Adjustment OtherComprehensiveIncomeRealizedGainAdjustment	364929	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-6529487	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-4416609	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	55712	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	49391	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	699505	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	477062	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	63420	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	356700	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-6875	usd
CY2023	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	135293	usd
CY2022	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	76190	usd
CY2023	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	364929	usd
CY2022	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	0	usd
CY2023	nuro	Compensation Obligation Settlement CompensationObligationSettlement	0	usd
CY2022	nuro	Compensation Obligation Settlement CompensationObligationSettlement	26019	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-127947	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	335953	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7861	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1265134	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	188109	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	181805	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-152573	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	84046	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	346800	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-13818	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6084868	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5289416	usd
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	29755105	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	usd
CY2023	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	0	usd
CY2022	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	40933126	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	14095000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	usd
CY2023	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	17000000	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	24144609	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	183542	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	23182	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1156353	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16811699	usd
CY2023	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	2325441	usd
CY2022	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3864031	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2325441	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3864031	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2603074	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-18237084	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4335020	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22572104	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1731946	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4335020	usd
CY2023	nuro	Stock Issuance Settle Incentive Compensation Obligation StockIssuanceSettleIncentiveCompensationObligation	0	usd
CY2022	nuro	Stock Issuance Settle Incentive Compensation Obligation StockIssuanceSettleIncentiveCompensationObligation	189398	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	18000000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates and Assumptions</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances and regularly assesses these estimates, but actual results could differ materially from these estimates. Effects of changes in estimates are recorded in the period in which they occur.</span></div>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash equivalents, trade receivables, and securities. The Company invests its cash equivalents and securities in highly rated institutions.</span></div>At December 31, 2023 and 2022, three customers accounted for 74% and two customers accounted for 31% of accounts receivable, respectively. Two customers accounted for 34% of revenues for the year ended December 31, 2023 and one customer accounted for 32% of revenues, for the year ended December 31, 2022.
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	25000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	25000	usd
CY2023Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	9400	usd
CY2022Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	16700	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6529487	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6529487	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4416609	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4416609	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1041991	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1041991	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	889540	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	889540	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.27
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.27
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.97
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.97
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	131381	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	102063	shares
CY2023	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	132806	usd
CY2022	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	268703	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	240171	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	usd
CY2023	nuro	Sales Revenue Goods Net Percentage From Foreign Country SalesRevenueGoodsNetPercentageFromForeignCountry	0.20
CY2022	nuro	Sales Revenue Goods Net Percentage From Foreign Country SalesRevenueGoodsNetPercentageFromForeignCountry	0.14
CY2023	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	4902	shares
CY2022	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	2526	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.700
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	65662	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	26.15
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	40.21
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	3	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	4224
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	64659	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	25.73
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	61773	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	25.74
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y9M18D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	61773	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	25.74
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y9M18D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	30.72
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	36885	usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	5500	shares
CY2023Q4	nuro	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Price Per Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAveragePricePerShares	25.40
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	27.20
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	699505	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	477062	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	698854	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y4M24D
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	16025034	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	240171	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	16265205	usd
CY2023Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	91502	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	14256	usd
CY2022Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	16864707	usd
CY2022Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	16794874	usd
CY2023Q4	us-gaap	Debt Securities Held To Maturity Allowance For Credit Loss DebtSecuritiesHeldToMaturityAllowanceForCreditLoss	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	17549495	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	1551027	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1151381	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	982129	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	408047	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	632858	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1559428	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1614987	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	63420	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	356700	usd
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	131621	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	41888	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	37394	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	876739	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	589939	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1030172	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	846630	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	736723	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	681011	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	293449	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	165619	usd
CY2023	us-gaap	Depreciation Depreciation	55712	usd
CY2022	us-gaap	Depreciation Depreciation	49391	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	298534	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	155000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	346245	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	249224	usd
CY2023Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	9400	usd
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	16700	usd
CY2023Q4	nuro	Accrued Clinical Current AccruedClinicalCurrent	39000	usd
CY2022Q4	nuro	Accrued Clinical Current AccruedClinicalCurrent	0	usd
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	141672	usd
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.010
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.049
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.001
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.001
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.020
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.033
CY2023	nuro	Effective Income Tax Rate Reconciliation382 Limitation EffectiveIncomeTaxRateReconciliation382Limitation	0
CY2022	nuro	Effective Income Tax Rate Reconciliation382 Limitation EffectiveIncomeTaxRateReconciliation382Limitation	0.174
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.239
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.465
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4289409	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3369688	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	544415	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	310000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	44497	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	74459	usd
CY2023Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	97378	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	88983	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	311039	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	323337	usd
CY2023Q4	nuro	Deferred Tax Assets Right Of Use Assets DeferredTaxAssetsRightOfUseAssets	56481	usd
CY2022Q4	nuro	Deferred Tax Assets Right Of Use Assets DeferredTaxAssetsRightOfUseAssets	87872	usd
CY2023Q4	nuro	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	1131902	usd
CY2022Q4	nuro	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	719888	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1596	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	6476717	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4974227	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6418062	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4868469	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	58655	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1524939	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1524939	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	971492	shares
CY2023Q4	nuro	Income Tax Expense Benefit Attributable To Net Operating Loss Carry Forward IncomeTaxExpenseBenefitAttributableToNetOperatingLossCarryForward	2400000	usd
CY2023Q4	nuro	Income Tax Expense Benefit Attributable To Tax Credit Carry Forwards IncomeTaxExpenseBenefitAttributableToTaxCreditCarryForwards	75000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6400000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4900000	usd
CY2023Q4	nuro	Nol And Tax Credit Carryforwards Eliminated NOLAndTaxCreditCarryforwardsEliminated	123800000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	0	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	22795	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	165785	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	117431	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	283216	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.150
CY2023Q4	nuro	Operating Lease Discount OperatingLeaseDiscount	42340	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	148391	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	92485	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	283216	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	197310	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	163061	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M12D
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	usd
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	usd
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	971492	shares
CY2023	us-gaap	Common Stock Voting Rights CommonStockVotingRights	Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders.
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	173924	shares
CY2023Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-8 reverse stock split of its Common Stock
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8733398	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1091648	shares

Files In Submission

Name	View Source	Status
0001628280-24-008267-index-headers.html	Edgar Link	pending
0001628280-24-008267-index.html	Edgar Link	pending
0001628280-24-008267.txt	Edgar Link	pending
0001628280-24-008267-xbrl.zip	Edgar Link	pending
ex2313124.htm	Edgar Link	pending
ex3113124.htm	Edgar Link	pending
ex3123124.htm	Edgar Link	pending
ex323124.htm	Edgar Link	pending
ex97compensationrecoverypo.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nuro-20231231.htm	Edgar Link	pending
nuro-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
nuro-20231231_cal.xml	Edgar Link	unprocessable
nuro-20231231_def.xml	Edgar Link	unprocessable
nuro-20231231_lab.xml	Edgar Link	unprocessable
nuro-20231231_pre.xml	Edgar Link	unprocessable
nuro-20231231_htm.xml	Edgar Link	completed
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NURO
NeuroMetrix, Inc. Stock $nuro

2024 Q1 Form 10-K Financial Statement

#000162828024008267 Filed on March 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NURO NeuroMetrix, Inc. Stock $nuro

2024 Q1 Form 10-K Financial Statement

#000162828024008267 Filed on March 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NURO
NeuroMetrix, Inc. Stock $nuro